DEFINING

TOMORROW.

We are a national Saudi manufacturer

who offers high quality pharmaceutical products

About Kinnova

~300 million

Units Per Year.

10,000 square meters manufacturing facility

in the Oasis of Modon in Qassim industrial region.

More About Us

About Us

Kinnova was established in 2022

It has a manufacturing facility (under construction) in the Oasis of Modon in Qassim industrial region.

The plant is approximately 10,000 square meters having a secondary packaging & area as Phase-1 and oral Solid line sterile injectable line as Phase-2, with total annual capacity 500~million units.
As an important strategic asset Kinnova currently has (+50) potential super-selected Products at the SFDA.

Location, Accessibility & Facility Details:

Strategic Location: The Kinnova site is located just a 10-minute drive from central Buraidah, a city with a population of 1 million.
Total land areа: 18,000 square meters.
Plant building area: Approximately 10,000 square meters.

10,000 Square Meters.

OUR VISION

Kinnova is committed to delivering innovative health solutions to the community. This vision is realized through:

Developing and producing high-quality pharmaceutical products
Localizing the manufacturing of Pharmaceutical
products in line with Saudi Vision 2030,
contributing to the Kingdom’s economic
diversification and self-sufficiency in healthcare.

OUR MISSION

Provide integrated healthcare solutions & services that significantly cover the full pharmaceutical value chain starting from R&D and registration stages to marketing and distribution.

TEAM

We employ our long experience in the field of pharmaceutical and healthcare and our knowledge of local regulations in the Kingdom of Saudi Arabia to provide comprehensive and integrated solutions, starting from the stage of product registration in the Saudi market until the stage of marketing and distribution, which provides easy market access and speed of deployment and expansion under one roof.

Construction Status:

Foundation & Underground Tanks: Completed
Steel Erection: Completed
External Wall:Underway, with completion targeted before the end of 2025
Electromechanical Works: Underway.
MMF (MODULAR MOBILE FACILITY): Received.

(2025-2028)

Construction Plan:

Stage 1:

Secondary Packaging Area & Warehouses (Target Completion and SFDA GMP Approval: Q4-2026)

Stage 2:

Solid production Line & Main laboratories (Target Completion and SFDA GMP Approval: Q4- 2027)

Stage 3:

Sterile production Line (MMF) & Secondary Packaging Area (Target Completion and SFDA GMP Approval: Q4-2028)

QUALITY

RELIABILITY

COMMITMENT

FLEXIBILITY

COLLABORATION

OUR

VALUES

QUALITY

We work with the highest quality standard to build reputation in the Saudi market among patients, customers, partners & shareholders.

RELIABILITY

We harness our expertise and deep knowledge in the field of the pharmaceutical sector in Saudi Arabia that distinguishes us to achieve the desired goals with distinction.

COMMITMENT

We are committed to fulfilling the requirements of the customers and partners in accordance with the specifications and the agreed period of time, and we continue to review the latest local regulations from the competent authorities.

FLEXIBILITY

We are open to various solutions and ideas that meet the aspirations of our customers and partners through the services we provide to them, at all stages and we positively respond to the market dynamics.

COLLABORATION

We build trust with partners because we do believe it is the key to the success and continuation of fruitful long-term partnership.

Development Capabilities

INJECTABLE FORMS

PFS, LIQUID VIALS

6M UNITS/YEAR

SOLID DOSAGE FORMS

IMMEDIATE, DELAYED, SUSTAINED

120M TABLETS & CAPSULES /YEAR

SEMI SOLID FORMS+

CREAM, OINTMENT, GEL

6M TUBES/YEAR

OUR PARTNERS

Strategic Therapeutic Areas (TAs)

PORTFOLIO & PIPELINE

he pipeline includes wellselected synergized products, the company relies on both the R&D capabilities and the Business Development & Licensing through signing License & Supply Agreements with International Companies that are then followed by Tech Transfer and full localization of the manufacturing Know-how.